Time change of Analyst briefi

RNS Number : 9567W

Oxford Biomedica PLC

06 August 2009

 



This announcement is to replace RNS number: 8693W. Please note that there has been a change made to the timing of the Analyst briefing and the webcast. Both will now commence at 10:30am.

For Immediate Release	6 AUGUST 2009

OXFORD BIOMEDICA: NOTICE OF 2009 INTERIM RESULTS

RESULTS DATE: 27 AUGUST 2009

TIME CHANGE: ANALYST MEETING AND WEBCAST NOW TO BE HELD AT 10:30AM

Oxford, UK - 5 August 2009: Oxford BioMedica (LSE: OXB), a leading gene therapy company, today announces that it will be releasing its interim results for the six months ended 30 June 2009 on Thursday, 27 August 2009.

Analyst meeting: An analyst briefing will be held at 10:30am on Thursday, 27 August 2009 at the offices of Buchanan Communications, 45 Moorfields, London EC2Y 9AE. 

Web cast: Simultaneously to the analyst briefing at 10:30am, there will be a live audio web cast of the presentation. To connect to the web cast facility, please go to the Company's website: http://www.oxfordbiomedica.co.uk/ approximately 10 minutes (10:20am) before the start of the briefing. This will also be available for replay shortly after the presentation.

-Ends-

For further information, please contact:
Oxford BioMedica plc:  John Dawson, Chief Executive Officer Nick Woolf, Chief Business Officer	Tel: [phone]
JPMorgan Cazenove Limited: James Mitford/ Gina Gibson	Tel: [phone]
Media/Financial Enquiries: Lisa Baderoon/ Mark Court/ Mary-Jane Elliott Buchanan Communications	Tel: [phone]
US Enquiries: Thomas Fechtner The Trout Group LLC	Tel: [phone]

Notes to editors

1. Oxford BioMedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient gene delivery system (LentiVector®), which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline. Partners include sanofi-aventis, Sigma-Aldrich and Wyeth. Technology licensees include Biogen Idec, GlaxoSmithKline, Merck & Co and Pfizer. Further information is available at www.oxfordbiomedica.co.uk

 

END

 

 

MSCSSLFIISUSELA